50 Million euro investment for LUMC spin-off RougeTx advances therapies for inherited bleeding disorders.
Congratulations to Enzo Porrello, Sean Humphrey and team, who were awarded an NHMRC Synergy grant, that aims to better dilated cardiomyopathy and potentially find new therapies.
The grant, led by reNEW Melbourne’s node director Professor Enzo Porrello, who is also a group leader at Murdoch Children’s Research Institute, was awarded $5 million from the National Health and Medical Research Council (NHMRC).
These NHMCR grants are designed to support Australia’s highest-performing researchers.
Dilated cardiomyopathy (DCM), the leading cause of heart failure in children. Many young people with a DCM diagnosis may also require a heart transplant.
The funding will enable the team to integrate elements of genomics, proteomics, stem cell modelling, patient data and AI tools together into a streamlined platform that could lead to new drug treatment options for DCM.
Joining Porrello is reNEW’s Functional Phosphoproteomics Platform Manager Dr Sean Humphrey.
“As far as heart conditions go, DCM is fairly common and can lead to heart transplants, but despite this our current treatment options only target the symptoms and not the underlying causes of the disease,” Professor Porrello said.
“This research will help us to better understand what issues occur in human heart tissue affected by DCM and how new or existing drugs may alleviate these problems.”
Researchers from the Garvan Institute of Medical Research and Gladstone Institutes will also contribute to the study.
These grants recognise the strength of our research in tackling the biggest health challenges for Australians.
